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22q11.2 Deletion Syndrome (22q11.2DS) is a common microdeletion syndrome with congenital and late-onset
features. Testing for the genomic content of copy number variations (CNVs) may help elucidate the 22q11.2
deletion mechanism and the variable clinical expression of the syndrome including the high (25%) risk for
schizophrenia. We used genome-wide microarrays to assess CNV content and the parental origin of
22q11.2 deletions in a cohort of 100 adults with 22q11.2DS (44 with schizophrenia) and controls.
22q11.2DS subjects with schizophrenia failed to exhibit de novo CNVs or any excess of novel inherited
CNVs outside the 22q11.2 region. There were no signiﬁcant effects of parental origin of the 22q11.2 deletion,
deletion length, parental age or family history on expression of schizophrenia. There was no evidence for
a general increase of de novo CNVs in 22q11.2DS. A novel ﬁnding was the relative paucity of males with
de novo 22q11.2 deletions of paternal origin (P 5 0.019). The Y chromosome may play a mediating role in
the mechanism of 22q11.2 deletion events during spermatogenesis, resulting in the previously observed
excess of maternal de novo 22q11.2 deletions. Hemizygosity of the 22q11.2 region appears to be the major
CNV-related risk factor for schizophrenia in 22q11.2DS. The results reinforce the need for further efforts to
identify speciﬁc molecular mechanisms underlying this expression and to identify the 1% of patients with
schizophrenia who carry 22q11.2 deletions.
INTRODUCTION
22q11.2 deletion syndrome (22q11.2DS), also known as velo-
cardiofacial syndrome or DiGeorge syndrome (MIM nos
188400, 192430), is the most common microdeletion syn-
drome, occurring in approximately one in every 4000 live
births (1). De novo 22q11.2 deletions (approximately 90%)
are more common than inherited deletions (approximately
10%) in newly diagnosed patients. The high recurrence rate
of these mutations is related to the presence of low-copy
repeat sequences, which predispose the 22q11.2 region to
structural rearrangement (2,3). A slight excess of de novo
22q11.2 deletions arising on the maternally inherited chromo-
some is unexplained (4,5).
The 22q11.2DS phenotype is highly variable with features
including velopharyngeal insufﬁciency, congenital cardiac
defects and learning difﬁculties. Most 22q11.2DS cases,
however, share similar 3 Mb hemizygous microdeletions,
suggesting that factors other than deletion length might con-
tribute to variable clinical expression (6,7).
Adults with 22q11.2DS have a rate of schizophrenia
approaching 25%, whereas in the general population approxi-
mately 1% of schizophrenia is associated with 22q11.2
deletions (8,9). It is likely that there are elevated rates of
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lation (10). In addition to recurrent 22q11.2 deletions, recent
reports (11–14) provide some evidence for elevated rates of
rare novel CNVs and/or recurrent CNVs in schizophrenia.
These studies suggest that CNVs at loci other than 22q11.2
may contribute to the expression of schizophrenia in
22q11.2DS. To test this hypothesis and to examine character-
istics of the 22q11.2 deletion itself, we scanned the genomes
of a cohort of 100 Canadian adults diagnosed with 22q11.2DS.
RESULTS
Genome-wide copy number variation
Table 1 summarizes the 22q11.2DS-related deletions observed
in this study. Table 2 summarizes CNVs detected elsewhere in
the genome. We found no evidence for an excess of CNVs or
any speciﬁc targeted CNV regions in subjects with 22q11.2DS
and schizophrenia, or in 22q11.2DS overall compared with
controls. We were also able to compare the CNV content
between 65 unaffected parents in whom de novo 22q11.2 dele-
tions were conﬁrmed not to have arisen and 53 unaffected
parents on whose chromosome 22 the 22q11.2 deletions
were conﬁrmed to have arisen as de novo events. These ana-
lyses showed no signiﬁcant differences between these two
groups of parents in number, size and proportion of losses of
genome-wide CNVs (Supplementary Material, Table S1).
There was only one conﬁrmed de novo CNV outside the
22q11.2 region (a 636 kb gain at 4q35.1) that occurred in a
non-psychotic 22q11.2DS proband. This is within the expected
rates, given a de novo mutation rate of approximately 1% at
this resolution of analysis in control populations (15). Inspec-
tion of approximately 100 inherited CNVs in subjects with
22q11.2DS revealed on average fewer regions of interest in
this study than in our recent study of autism spectrum dis-
orders (16). There was a novel recurrent/overlapping CNV
at 18p11.31 in four subjects with 22q11.2DS and schizo-
phrenia, three with 8.5–10 kb losses that were not validated
with quantitative polymerase chain reaction (qPCR) and one
with a conﬁrmed 338 kb gain inherited from an unaffected
parent. Although a possible region of interest for psychotic
disorders (17,18), the CNV region contained no genes. Sup-
plementary Material, Tables S2 and S3 show all CNVs,
besides the major 22q11.2 deletion, in subjects with
22q11.2DS and their unaffected parents, respectively.
22q11.2 deletions and related copy number variations
The majority (83/94; 88.3%) of probands with 22q11.2DS
had the common 3 Mb 22q11.2 deletion. The other 11 pro-
bands carried one of eight variants of the 22q11.2 deletion
(Table 1). Single nucleotide polymorphism (SNP) array
results broadly agreed with qPCR results previously published
for 44 of the subjects (7) (Table 1). Subjects with schizo-
phrenia carried the typical (39/44; 88.6%) or one of the
three variant 22q11.2 deletion breakpoints.
We also examined the 22q11.2 deletion region for CNVs
that could predispose to deletion formation. As expected in
this region, there were polymorphic CNVs in some parents,
including two on whose chromosome the deletion had arisen.
A rare 142 508 bp loss (17 269 780–17 412 288), involving
the typical 22q11.2 deletion’s proximal breakpoint, was found
Table 1. 22q11.2 deletions in 94 adult probands with 22q11.2 deletion syndrome (22q11.2 DS)
Deletion type Current study Previous study
Subjects with 22q11.2DS (n ¼ 94
probands)
Estimates of 22q11.2 deletion breakpoints using
Affymetrix NspI 250K SNP array and 3 algorithms
(NCBI Build 35)
Clinical FISH
probe
b
qPCR (n ¼ 44)
c
(7)
Total Conﬁrmed origin of 22q11.2
deletion
n % Inherited
a
(n ¼ 5)
De novo
(n ¼ 65)
Proximal start
point
Distal end
point
Minimum length
(Mb)
Similar results
Short variant 1 1 1 16, 323, 500 18, 285, 270 2.0 2/þ –
Long nested 1 1 17, 269, 780 19, 067, 004 1.8 2/þ Yes (n ¼ 1)
Short nested 3 3 2 17, 269, 780 18, 697, 764 1.4 2/þ –
Short proximal
variant 1
11 1 17, 412, 288 18, 697, 764 1.3 2/þ –
Proximal variant 1
a 22 1 1 17, 412, 288 19, 786, 161 2.4 2/þ Yes (n ¼ 2)
Proximal variant 2 1 1 1 17, 490, 048 19, 786, 161 2.3 2/þ –
Atypical 1
b 1 1 1 17, 774, 335 19, 786, 161 2.0 þ/þ Yes (n ¼ 1)
Atypical 2
b 1 1 1 18, 147, 862 19, 786, 161 1.6 þ/þ Yes (n ¼ 1)
Typical
c 83 88 4 57 17, 269, 780 19, 786, 161 2.5 2/þ Yes (n ¼ 39)
3
Typical start and end points of 22q11.2 deletions are shaded. Recurrent start and end points are shown in bold.
aOne subject was assumed to have inherited a proximal variant 1 deletion (DNA unavailable for copy number variation (CNV) analysis from the mother with
22q11.2 DS but clinical ﬂuorescence in situ hybridization (FISH) results had conﬁrmed a 22q11.2 deletion). Four inherited typical 22q11.2 deletions were
conﬁrmed with CNV results available from parents.
b2/þ Denotes hemizygous 22q11.2 deletion on standard clinical FISH testing using TUPLE1 or N25 probe. þ/þ Denotes 22q11.2 deletion not detected on
clinical FISH testing. Two atypical 22q11.2 deletions were conﬁrmed with FISH using probe COMT in a quantitative polymerase chain reaction (qPCR) study (7).
Conﬁrmatory FISH data were thus available for all 100 subjects with 22q11.2DS (94 probands, ﬁve transmitting parents, one half sibling).
cqPCR results using 21 markers available for the 39 subjects in the current study with apparently typical 22q11.2 deletions showed that 34 subjects had the same
typical 22q11.2 deletion and ﬁve had variant distal breakpoints beyond the resolution of the single nucleotide polymorphisms (SNPs) in this study (7). The SNP
array study provided more details on proximal breakpoints but less details on distal breakpoints than the qPCR study (7).
4046 Human Molecular Genetics, 2008, Vol. 17, No. 24Table 2. Genome-wide copy number variants (CNV) in 22q11.2 deletion syndrome (22q11.2 DS) with and without schizophrenia and in unaffected parents
250K Affymetrix array 22q11.2DS study 500K Affymetrix
array (13)
22q11.2DS patients
a (n ¼ 95) Unaffected
parents
a
(n ¼ 122)
Popgen controls
(n ¼ 500)
22q11.2DS
Schizophrenia versus
non-psychotic
b
All 22q11.2DS
patients versus
unaffected parents
b
All (n ¼ 95) Schizophrenia
(n ¼ 42)
Non-psychotic
(n ¼ 53)
Statistic df P Statistic df P
Total number of CNV 494 209 285 657 3695
Stringent
b 216 91 125 286 1558
Average CNV per genome 5.2 5 5.4 5.4 7.4
Stringent
b 2.3 2.2 2.4 z ¼ 21.20 – 0.2 2.3 z ¼ 20.43 – 0.7 3.1
Median size in kb (range) 177 (3–1987) 177 (3–1987) 181 (3–1987) 194 (2–2731) 151
Stringent
b 212 (14.8–
1987)
211 (24.7–
1987)
215 (14.8–
1987)
z ¼ 20.36 – 0.7 206 (3–2731) z ¼ 20.51 – 0.6 224
Number .1 Mb CNV (% of total) 45 (9.1%) 19 (9%) 26 (9.1%) 72 (10.9%) 343 (9%)
Stringent
b 28 (13%) 13 (14.3%) 15 (12%) x
2 ¼ 0.24 1 0.6 46 (16.1%) x
2 ¼ 0.95 1 0.3 250 (16%)
Losses, % of total 36% 35.4% 36.5% 37.6% 41%
Stringent
b 40.3% 36.3% 43.2% x
2 ¼ 1.05 1 0.3 40.6% x
2 ¼ 0.004 1 1.0 30%
Number of novel CNV (% of total) 100 (20.2%) 42 (20.1%) 58 (20.4%) 117 (18.1%) 690 (19%)
Stringent
b [number of different loci involved] 39 (18.1%) [39] 18 (19.8%) [18] 21 (16.8%) [21] x
2¼0.32 1 0.6 44 (15.4%) [43] x
2 ¼ 0.64 1 0.4 237 (15.2%) [219]
aAll 22q11.2 deletions shown in Table 1 were excluded as CNV in the 22q11.2DS patient group. No unaffected parent had a 22q11.2 deletion as shown in Table 1. CNV data for Popgen controls
(13) are provided for comparison. Sample derivations are described in the text.
bAnalysis using stringent data set, i.e. called using more than one algorithm or array (see Materials and Methods for further details).
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7with one algorithm in a proband and unaffected father on whose
chromosome arose the 22q11.2 deletion with an atypical prox-
imal breakpoint about 360 kb distal at 17 774 335 (Atypical 1,
Table 1). The rarity of this CNV in control populations
(0.2–0.8%) (16,19) makes it possible that it was a factor in
the origin of this atypical deletion which is estimated to com-
prise ,1% of all 22q11.2 deletions identiﬁed (6). However,
there was no evidence that this or any other CNV in the
22q11.2 region predisposed to other 22q11.2 deletion events.
Parental origin of 22q11.2 deletions and expression
of schizophrenia
Expression of schizophrenia was not related to inherited or de
novo status of 22q11.2 deletions. Of the probands with inher-
ited 22q11.2 deletions (Fig. 1), three of seven (42.9%; one
conﬁrmed, two probable) had schizophrenia. Of the 65 pro-
bands with conﬁrmed de novo deletions (Table 1), in whom
parental origin of deletion could be resolved for 60 (Fig. 1),
there were no signiﬁcant differences in parental origin of de
novo 22q11.2 deletion between the schizophrenia (14/26,
53.9% maternal) and non-psychotic groups (22/34, 64.7%
maternal; x
2 ¼ 0.72, df ¼ 1, P ¼ 0.39), or in mean intellectual
level (IQ) between probands with maternal or paternal origin
of de novo 22q11.2 deletion (70.8, SD 7.9 versus 71.9, SD
9.5, respectively; t ¼ 20.48, df ¼ 22, P ¼ 0.63). IQ results
were similarly non-signiﬁcant within the schizophrenia sub-
group (data not shown).
Other factors examined also showed no evidence that they
signiﬁcantly affected risk for schizophrenia in 22q11.2DS.
In ﬁrst-degree relatives, with ﬂuorescence in situ hybridization
(FISH) data conﬁrming no 22q11.2 deletion, there was a
family history of psychotic illness in two of 44 (4.5%) subjects
with schizophrenia and one of 56 (1.8%) in the non-psychotic
group. There were no signiﬁcant differences between these
groups in maternal or paternal age (data not shown).
Sex distribution and parental origin of 22q11.2 deletions
Table 3 shows the sex distribution of probands with conﬁrmed
de novo 22q11.2 deletions and known parental origin. As pre-
viously observed in 22q11.2DS, we found a non-signiﬁcant
excess of de novo maternal deletions (60%; P ¼ 0.12).
Further analyses showed that this was associated with sex of
the offspring, with males signiﬁcantly less likely than
females to have a de novo 22q11.2 deletion of paternal
origin [relative risk (RR) ¼ 0.44, 95% CI ¼ 0.20–0.94; P ¼
0.019]. This appeared to be due to an unexpected paucity of
males with deletions arising on paternally inherited chromo-
somes (Table 3). Results were similar for an expanded
sample (Fig. 1) including nine subjects with ‘probable’ de
novo origin of 22q11.2 deletion (RR ¼ 0.47, 95% CI ¼
0.25–0.91; P ¼ 0.014). Similar rates of subjects with schizo-
phrenia were present in all four of the possible groups (data
not shown) and there was no signiﬁcant difference in sex
distribution between the schizophrenia (20 male, 24 female)
and non-psychotic (24 male, 32 female) 22q11.2DS groups
(x
2 ¼ 0.07, df ¼ 1, P ¼ 0.80).
We expanded our examination of skewed sex distribution
to include unaffected full sibling live births. Tests of equal
Figure 1. 22q11.2DS, copy number variants (CNVs) and parental origin of deletion. Summary of samples used for genome-wide CNV analyses and of results for
analyses of parental origin of 22q11.2 deletions. Conﬁrmed results for parental origin of deletion are based on CNV and ﬂuorescence in situ hybridization (FISH)
data for 46 trios and 19 duos. In six cases, FISH results allowed inference of a de novo (n ¼ 5) or inherited (n ¼ 1) 22q11.2 deletion when parental DNA was
unavailable and, in ﬁve cases CNV results for siblings helped conﬁrm parental origin. Probable results are based on CNV and FISH data for 11 duos, sup-
plemented with clinical data for the parent whose DNA was unavailable for study.
4048 Human Molecular Genetics, 2008, Vol. 17, No. 24proportions showed no signiﬁcant differences in the six families
with male probands of paternal de novo origin 22q11.2 dele-
tions (three brothers, ﬁve sisters), 18 families with female pro-
bands of paternal origin (18 brothers, 21 sisters), 16 with female
probands of maternal origin (14 brothers, 16 sisters) and 20
families of male probands of maternal origin (18 brothers, 14
sisters). There were also no signiﬁcant differences in maternal
or paternal age between subjects with maternal or paternal
de novo origin of deletion overall or when male and female
probands were examined separately (data not shown).
DISCUSSION
Our results suggest that the expression of schizophrenia in
individuals with 22q11.2DS primarily arises from effects
related to the 22q11.2 deletion itself. There was no indication
that other CNVs elsewhere in the genome or that the parent of
origin of de novo 22q11.2 deletions inﬂuenced the schizo-
phrenia phenotype. An interesting observation was that the
previously observed maternal excess of 22q11.2 deletions
appears to be related to a relative paucity of 22q11.2 deletions
of paternal origin in males, that is, in those deletions arising
during spermatogenesis and segregated with a Y chromosome
in the resulting sperm.
Expression of schizophrenia in 22q11.2DS
In contrast to the recent reports for schizophrenia in the
general population (11–14), we found no evidence for an
overall increase in novel genome-wide CNVs in 22q11.2DS.
There was also no indication in our sample that speciﬁc recur-
rent CNVs, other than 22q11.2 deletions, were associated with
expression of schizophrenia. While some rarer CNVs may be
involved in increasing risk for schizophrenia in individual
cases in the general population (11,13,14,20), these do not
appear to be a necessary additional mechanism in the
expression of schizophrenia in individuals with 22q11.2 dele-
tions. We found no signiﬁcant effects of parental origin of the
22q11.2 deletion, deletion length, paternal age or family
history of psychotic illness on developing schizophrenia in
22q11.2DS. Our results are consistent with those showing no
relationship of parental origin of de novo 22q11.2 deletions
and expression of attention deﬁcit hyperactivity disorder or
obsessive–compulsive disorder in 22q11.2DS (21). Previous
results using small samples that have suggested a parental
origin of deletion effect on neuropsychiatric expression (22)
are likely to be spurious. Collectively, these results provide
no support for imprinting effects on neuropsychiatric
expression in 22q11.2DS (23). Hemizygosity of the 22q11.2
region appears to be the main factor in neuropsychiatric
expression in the syndrome (9).
Notwithstanding our negative statistical results, we com-
pared individual CNVs in our 22q11.2DS sample to those
reported in recent studies of schizophrenia from the general
population that used various ascertainment strategies but
similar CNV detection methods and diagnostic criteria
(DSM-IV) (11–14) (Supplementary Material, Table S4). We
were particularly interested in determining any overlap
between individual non-22q11.2 deletion CNVs in our
22q11.2DS subjects with schizophrenia and those reported in
these studies. Five subjects with schizophrenia from our
sample had CNVs that shared some similarities in position,
though not necessarily loss/gain status or length, to three
CNVs reported in these studies. One 22q11.2DS subject
with schizophrenia had a 1.48 Mb loss at 15q13.2-15q13.3
(chr 15:28,748,100-30,231,500) that was inherited from an
unaffected parent. This CNV, in a region ﬂanked by segmental
duplications, has previously been reported in controls (chr
15:28,393,128-30,740,356; variation_8795) (24) as has a
large inversion (chr 15:28,524,307-30,602,466) in this region
(25). The CNV we observed was similar in position but
approximately 100 kb smaller than the 1.54–2.47 Mb losses
reported in 15 patients with schizophrenia and eight controls
in two multi-site studies with slightly overlapping samples
(13,14). Interpretation of these ﬁndings will be aided by
further data on ethnicity of samples and the phenotype of con-
trols and inheritance of this CNV in schizophrenia. Three sub-
jects with 22q11.2DS and schizophrenia had large (.1.6 Mb)
losses at 15q11.2, one of which was inherited from an
unaffected parent. We found similar CNVs in 20 (16.4%)
unaffected parents who did not transmit this CNV to the
offspring with 22q11.2DS and in one non-psychotic proband
with 22q11.2DS. These 15q11.2 CNVs show partial
overlap with the proximal end of a 471 kb loss observed in
26 cases with schizophrenia and 79 controls in one study
(13). Both the large .1.6 Mb and more distal 471 kb CNVs
have previously been reported in controls (24). Finally, one
subject with 22q11.2DS and schizophrenia had inherited
from an unaffected parent a novel 141 kb gain in a 2q31.3
region with no genes but contained within the extent of a
2.5 Mb de novo loss reported in a patient with childhood-onset
schizophrenia (11). These comparisons with the literature
do not seem sufﬁciently compelling to modify our overall
conclusions with respect to CNVs, other than the 22q11.2
deletion, and expression of schizophrenia in 22q11.2DS.
Table 3. Conﬁrmed parental origin of de novo 22q11.2 deletions and sex distribution in 22q11.2 deletion syndrome (22q11.2 DS)
Probands with 22q11.2DS Parental origin of de novo 22q11.2
deletion
Analyses
Maternal Paternal Chi-square of equal
proportions of parental
origin
Relative risk (RR)
for maternal origin of
deletion in males
Overall chi-square of
parental origin by sex
n (%) n (%) x
2 df P RR 95% CI x
2 df P
Males 20 (33.3) 6 (10.0) 7.54 1 0.006 1.63 1.08–2.47 5.48 1 0.019
Females 16 (26.7) 18 (30.0) 0.12 1 0.73
Total (n ¼ 60) 36 (60.0) 24 (40.0) 2.40 1 0.12
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phrenia in 22q11.2DS? Altered expression of several genes
within the 22q11.2 region may be necessary to increase sus-
ceptibility of schizophrenia in 22q11.2DS (26–28). There is
some evidence that SNPs in certain genes within the
22q11.2 deletion region on the intact homologous chromo-
some may be involved. For example, we have found signiﬁ-
cant association with schizophrenia and the PIK4CA gene in
22q11.2DS (29) using the same SNPs as those found to be
associated in a general population sample of schizophrenia
(30). This is in contrast to the negative ﬁndings of the
COMT functional allele and schizophrenia in 22q11.2DS
(31). Other small genetic variants in candidate genes for
schizophrenia elsewhere in the genome may also modify the
large effects of the hemizygous 22q11.2 deletion, as shown
for other phenotypic features of 22q11.2DS (32,33). There
also remains the possibility that various individual CNVs
increase the likelihood of expressing schizophrenia in
22q11.2DS.
Origin of de novo 22q11.2 deletions
We found that males with 22q11.2DS who had a maternal
origin of a de novo 22q11.2 deletion were represented in a
similar proportion to females with either maternal or paternal
origin of deletion, but that males had a signiﬁcantly lower
chance of having a paternal origin of the deletion. This is con-
sistent with the meta-analyses of previous studies (4,5) and our
own results showing an excess of de novo deletions of
maternal origin in 22q11.2DS. Previous studies have not con-
sistently documented the sex distribution of patients however,
hampering further comparisons. Larger samples will be
needed to replicate the paucity of paternal origin of de novo
22q11.2 deletions in males which, although signiﬁcant,
could be due to chance in a relatively small sample.
Explaining this ﬁnding is difﬁcult. The mechanism under-
lying deletions in 22q11.2DS mainly involves non-allelic hom-
ologous recombination (NAHR) between misaligned low copy
repeats during gametogenesis (4,34). It is possible that there
is a female bias in NAHR causing de novo 22q11.2 deletions
(5). Our results suggest however that de novo 22q11.2 deletions
may occur with approximately equal frequency in oogenesis
and during spermatogenesis, but that somehow the Y chromo-
some affects the likelihood of observing a 22q11.2 deletion.
There is a sequence homology between the Yq12 region and
the low copy repeats, LCR22-2 and LCR22-4, that are most
commonly involved in the 22q11.2 interchromosomal
exchanges and NAHR that give rise to 22q11.2 deletions.
These regions share a 2.4 kb human satellite sequence subclass
involving AT-rich tripartite repeats (35). Babcock et al.( 3 5 )
have posited that these repeat elements may play a structural
role in mediating NAHR between LCR22-2 and LCR22-4 if
the presence of the Yq12 repeat prevents recombination
between the LCRs, thereby enhancing meiotic stability of the
22q11.2 region. Such a mechanism could be related to physical
proximity of these heterochromatic regions in the nuclear per-
iphery (35,36). The report of a subject with 22q11.2DS resulting
from a de novo Y;22 translocation (37) may be consistent with
interchromosomal interaction between these chromosomes. To
explain the possibility that, in sperm with a 22q11.2 deletion
chromosome, there may be an elevated ratio of those with an
X to those with a Y chromosome, however, would appear to
implicate the segregation process, as a spermatocyte with a de
novo 22q11.2 mutation would have both sex chromosomes
present. One could speculate that proximity of the Y chromo-
some to the deletion chromosome 22 could interfere with
normal segregation and/or error correction, resulting in an unba-
lanced, non-viable sperm (38), e.g. with two deletion 22q11.2
chromosomes.
Studies of sperm could help investigate possible mechan-
isms. Further studies of NAHR and allelic homologous recom-
bination (AHR, i.e. normal meiotic recombination) in
3-generation families are also needed to determine whether
polymorphic size of LCRs in the 22q11.2 region (39) or clus-
tering of recombination events within certain families and
high rates of AHR in the 22q11.2 region in female meiosis
(5) may also play a role in the observed sex distribution of
de novo 22q11.2 deletions.
Advantages and limitations
This is the largest sample of adults with 22q11.2DS, and one
of the largest ever investigated with respect to the parent of
origin of de novo 22q11.2 deletions (5). Nevertheless, there
were only six men with conﬁrmed paternal de novo origin of
the deletion. There were fewer fathers than mothers available
in parent–offspring pairs but a systematic ascertainment bias
appears unlikely to explain the results. Although including
the largest number of patients with 22q11.2DS-schizophrenia
yet studied, our sample size was relatively limited. However,
if there were a three-fold excess of genome-wide novel or
rare CNVs as proposed in a recent study (11), our sample
would have had sufﬁcient power to show this. Few subjects
(four of 56, 7.1%) in the non-psychotic group were younger
than the median age at onset of psychosis (20.5 years) and
there were no trends for differences between the schizophrenia
and non-psychotic subgroups on any CNV-related parameter
(Table 2), suggesting that misclassifying some subjects as non-
psychotic would not have materially affected the results.
CONCLUSIONS
In summary, hemizygosity of the 22q11.2 region seems to
confer the major CNV risk for the expression of schizophrenia
in 22q11.2DS. While further investigations are required to
determine molecular risk factors that mediate de novo
22q11.2 deletion events during gametogenesis, the results
reinforce the need for genetic counseling of individuals with
22q11.2DS about the risk for schizophrenia and further
efforts to identify the 1% of patients with schizophrenia who
carry 22q11.2 deletions.
MATERIALS AND METHODS
Subjects with 22q11.2DS
We diagnosed 100 Canadian adults (44 male, 56 female)
with 22q11.2DS originating from 94 families; six families
had two affected subjects (ﬁve parent–offspring pairs and
one half-sibling pair). All subjects met clinical screening
4050 Human Molecular Genetics, 2008, Vol. 17, No. 24criteria for 22q11.2DS in adults (40) and had conﬁrmed
chromosome 22q11.2 microdeletions using FISH and probes
from the 22q11.2 region (41) (Table 1). Observed ethnicity
of probands was 85/94 (90.4%) European, three of 94
(3.2%) African or mixed African, three of 94 (3.2%) Asian
and three of 94 (3.2%) other origins, consistent with the geno-
type data. Probands (median age 31.4; range 17.6–56.3)
were ascertained as previously described (8), many through
psychiatric sources or referrals, ensuring a high rate of
schizophrenia. Informed consent was obtained and the study
was approved by the Research Ethics Boards of the University
of Toronto, Centre for Addiction and Mental Health and
University Health Network.
All 22q11.2DS subjects had direct assessments, review of
medical records and information from relatives (8,31,42).
Lifetime psychiatric diagnoses were obtained by research
psychiatrists using standard methods and DSM-IV criteria
(31). Subjects with schizophrenia (n ¼ 37), schizoaffective
disorder (n ¼ 6) and psychotic disorder, not otherwise speci-
ﬁed (n ¼ 1), met the criteria for major psychotic disorders
[mean age at onset 20.9 (SD 5.4) years], collectively termed
‘schizophrenia’ for this study. The 56 other subjects comprised
the non-psychotic subgroup. Intellectual level was assessed
using standard methods to obtain Full Scale IQ (n ¼ 86) or
IQ estimates (n ¼ 8) (43). As expected (43), subjects with
schizophrenia were signiﬁcantly older (38.3, SD 9.8 versus
30.6, SD 10.6 years; t ¼ 3.74, P , 0.001) and had lower
mean IQ (68.6, SD 9.7 versus 73.0, SD 10.2; t ¼ 22.16,
P ¼ 0.03) than those in the non-psychotic group.
Parents
We included data for as many of the biological parents of this
adult sample as possible; no parental data existed for four pro-
bands who were adopted. Mean paternal and maternal ages at
birth for 96 subjects with 22q11.2DS were 31.3 (SD 5.8) and
27.9 (SD 4.7) years, respectively. FISH data conﬁrmed the
absence of a 22q11.2 deletion in 73 mothers and 64 fathers.
Extensive family history data from multiple sources provided
information on the demographics and health status of ﬁrst-
degree relatives, including common phenotypic features of
22q11.2 DS.
Copy number variation detection
We genotyped each available DNA sample [99 subjects with
22q11.2DS; 122 unaffected parents (69 mothers, 53 fathers);
ﬁve unaffected siblings] for approximately 250 000 SNPs
with the Affymetrix GeneChipw Human Mapping 250K
NspI Array according to established protocols (16,39,44).
Duos (proband and one parent) and trios (proband and both
parents) comprised the sample sets used to investigate parental
origin of de novo 22q11.2 deletions and inheritance of
genome-wide CNVs (Fig. 1).
NspI array scans were analyzed for CNV content with three
algorithms: DNA Chip Analyzer (dChip) (45,46), Copy
Number Analysis for GeneChip (CNAG) (47) and Genotyping
Microarray based CNV Analysis (GEMCA) (16,48). To mini-
mize potential batch effects, analysis with dChip was performed
in groups of approximately 50 probands/subjects according to
when the arrays were hybridized. For CNAG version 2.0, we
set the reference pool to include all samples and performed an
automatic batch pairwise analysis with sex-matched controls.
For GEMCA, we used two designated DNA samples
(NA10851andNA15510)as referencesfor pairwisecomparison
with all proband experiments. We further ﬁltered these results
by including only those CNVs that were common to both pair-
wise experiments. In all instances, CNVs were merged if they
weredetectedinthe sameindividual bymorethanone algorithm
with the outside probe boundaries (16). In general, CNAG
Merged (5.6/genome) and GEMCA (5.5/genome) algorithms
show more CNVs per genome than dChip Merged (3.0/
genome) (16). We report all data but in analyses we used a
‘stringent’ data set, i.e. CNVs called by more than one algor-
ithm, because these data have a high rate of validation (16).
Controls
Comparison control data comprised CNVs observed in 500
Europeans from the German PopGen project (16,49) and
entries in the Database of Genomic Variants (containing
8006 CNVs at 3933 loci) (24). A CNV was considered to be
‘novel’ in subjects if it was  10 kb, contained at least three
probes, and at least 20% of its total length was unique when
compared with controls. We also compared the results to
CNVs found in a cohort of 1152 non-disease controls of
European origin from the Ontario population that had been
analyzed using the same methods (16,19).
Parental origin of 22q11.2 deletions and other copy
number variations
We used SNP data to infer the parental origin of 22q11.2 dele-
tions for trios and a combination of SNP and FISH data for
duos. Where parent of origin could not be resolved using
SNP data, microsatellite marker analyses were performed
using 11 markers (sequence available upon request) across
the 22q11.2 region (16). For some duos, parent of origin
could be determined but that parent was unavailable for geno-
typic study. In those cases, we estimated whether 22q11.2 del-
etions were probably inherited or de novo in origin using the
available clinical data. We assigned a ‘probable inherited’
22q11.2 deletion status if the unavailable parent had two
or more major features of 22q11.2DS (40) and a ‘probable
de novo’ 22q11.2 deletion status if the unavailable parent
had none of these features and other offspring did not meet
the clinical criteria for 22q11.2DS (40).
Copy number variation validation of genome-wide copy
number variations
We validated all de novo and other potentially interesting
novel CNVs (16). Position coordinates were determined
using NCBI Build 35, and results were conﬁrmed using inheri-
tance patterns and qPCR.
Statistical analysis
Chi-square or two-sided Fisher’s exact tests and estimates of
relative risk with 95% CI were used to compare categorical
Human Molecular Genetics, 2008, Vol. 17, No. 24 4051variables. Wilcoxon rank sum tests were used to compare
ordinal data, and two-tailed Student’s t-tests for continuous
variables. Main comparisons were between schizophrenia
and non-psychotic groups on genome-wide CNVs and parent
of origin of de novo 22q11.2 deletions; we also examined
parental ages at birth and family history of psychotic illness
in ﬁrst-degree relatives. All analyses were performed using
SAS 9.1.3 (SAS Institute, Cary, NC, USA). P-values ,0.05
were considered signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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